HROW Earnings

HROW reported its earnings on 2026-03-02, showcasing a revenue of 89.09M against an estimate of 88.80M, resulting in a 0.33% surprise. The EPS was 0.26, surpassing the expected 0.4 by -35%. The stock experienced a -27.96% price change on the earnings day and a -32.17% change over the next five days, reflecting market reactions to the results.

Following HROW's earnings announcement on 2026-03-02, the stock price moved by -27.96% on the day of the release. Over the subsequent five days, it saw a -32.17% change. Historically, HROW's stock price tends to shift by an average of 2.44% in the 10 days leading up to earnings and 12.18% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate HROW's annual revenue to reach 68.68M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between HROW's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HROW's stock price typically moves by 2.44% in the 10 days before its earnings and 12.18% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.04 and revenue of 68.68M.

The earnings call highlighted strong product development and market strategy, with plans to launch new products and expand market reach. Despite a slight revenue guidance downgrade, optimistic future projections for products like VEVYE and TRIESENCE, and positive Q&A insights, bolster sentiment. The company's focus on expanding its sales force and improving product pricing further supports a positive outlook. The lack of specific guidance for some products was noted, but overall, the strategic initiatives and optimistic projections suggest a positive stock movement.